Johan Wäborg
CEO since 2020. Employed since 2020. Born 1977.
Background: Over 17 years’ of experience within commercial management, commercial development, new company establishment and business partnership roles in the pharmaceutical industry across multiple geographies including Nordics, Europe, Russia, Latin America, Middle East, Northern Africa.
Education: MSc, Chemical engineering, The faculty of engineering at Lund University (LTH) and ETH Zurich.
Other assignments: Board member and owner, Phigalia AB.
Previous assignments in the past five years: General Manager at Actelion Pharmaceuticals Sverige AB (Stockholm, Sweden). General Manager at Marklas BV (Woerden, Netherlands). Regional Director Business Support at Actelion Ltd (Basel, Switzerland). Actelion listed at SIX Swiss Exchange.
Holding: 74,286 shares
Orest Lastow
CTO and Founder since 2020. Employed since 2014. Born 1964.
Background: Over 30 years’ experience inhalation development, mainly from AstraZeneca. Invented more than nine different inhaler devices and been involved in
the development of 13 different inhaler devices. More than 40 patent applications and has published several research articles and books. Also co-authored the ISO standard for inhaler devices and is a frequently invited speaker at inhalation conferences. Founder of Iconovo and CEO 2014-2020.
Education: MSc, Engineering Physics, Lund University. PhD, Aerosol Physics, Brunel University, London.
Other assignments: Board member, Lastow Consulting AB and Torna Hällestad Fastighets AB.
Previous assignments in the past five years: Board member, XO Sweden Wines & Spirits AB.
Holding: 826,400 shares
Mikael Arinder
Vice President Operations since 2016. Employed since 2016. Born 1964.
Background: Over 14 years’ experience in the development of inhalation products from AstraZeneca and Iconovo. Has held roles as project manager for pharmaceutical, medical device and technology projects at AstraZeneca, J&J and Atos Medical.
Education: PhD, Organic Chemistry, Lund University.
Other assignments: -
Previous assignments in the past five years:
Holding: 19,178 shares
Vesna Åkerberg
Director Development since 2023. Employed since 2017. Born 1974.
Background: 14 years of inhalation experience, mainly from AstraZeneca and 10 years experience from line managerial positions in several companies, mainly from product/ process/ analytical development. Worked with product development within the pharmaceutical industry, mainly within formulation development of dry powder formulations. Experience from manufacturing of clinical trial material.
Education: MSc. Biomedical Technology
Holding: 2,651 shares
Roger Lassing
Vice President Business Development since 2019. Born 1965.
Background: Over 25 years’ experience of business development, marketing, sales and analysis from the pharmaceutical industry. Involved in more than 30 pharmaceutical transactions. Previous roles include VP in Business Development, Global Brand Manager for Symbicort at AstraZeneca, and Market Analyst at Astra Draco. Also worked three years at McKinsey & Co in the health care sector in Brussels.
Education: BSc in Business Administration and Economics, Lund University.
Other assignments: -
Previous assignments in the past five years: Senior Manager Global Business Development LEO Pharma.
Holding: 16,937 shares
Henrik Damkjær Simonsen
CFO since 2023. Born 1963.
Background: More than 30 years’ experience in life science with leading positions in banking and healthcare industry at Nordea, Skandinaviska Enskilda Banken (SEB), Nuevolution AB (publ) and SAGA Diagnostics AB.
Education: MSc in Economics, Copenhagen University.
Other assignments: -
Previous assignments in the past five years: Finance Director at SAGA Diagnostics AB and CFO at Nuevolution AB (publ).
Holding: -